TipRanks
Privia Health Group (PRVA)
NASDAQ:PRVA
US Market
PRVA
Privia Health Group
RESEARCH TOOLSreports
Want to see PRVA full AI Analyst Report?

Privia Health Group (PRVA) Stock Forecast & Price Target

221 Followers
See the Price Targets and Ratings of:

PRVA Analyst Ratings

Strong Buy
11Ratings
Strong Buy
10 Buy
1 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Privia
Health Group
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PRVA Stock 12 Month Forecast

Average Price Target

$31.80
▲(50.00% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Privia Health Group in the last 3 months. The average price target is $31.80 with a high forecast of $36.00 and a low forecast of $24.00. The average price target represents a 50.00% change from the last price of $21.20.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","28":"$28","37":"$37","23.5":"$23.5","32.5":"$32.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$36.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,23.5,28,32.5,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.03,21.25846153846154,22.486923076923077,23.715384615384615,24.943846153846152,26.17230769230769,27.40076923076923,28.62923076923077,29.857692307692307,31.086153846153845,32.31461538461538,33.543076923076924,34.77153846153846,{"y":36,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.03,20.935384615384617,21.840769230769233,22.746153846153845,23.65153846153846,24.556923076923077,25.462307692307693,26.36769230769231,27.273076923076925,28.17846153846154,29.083846153846153,29.989230769230772,30.894615384615385,{"y":31.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.03,20.335384615384616,20.64076923076923,20.946153846153848,21.251538461538463,21.556923076923077,21.86230769230769,22.16769230769231,22.473076923076924,22.77846153846154,23.083846153846153,23.38923076923077,23.694615384615386,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.71,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.41,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.04,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.07,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.85,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.31,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.88,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.67,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.64,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.03,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$36.00Average Price Target$31.80Lowest Price Target$24.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on PRVA
Ryan Halsted
RBC Capital
RBC Capital
$31
Buy
46.23%
Upside
Reiterated
10/06/26
RBC Capital Reaffirms Their Buy Rating on Privia Health Group (PRVA)
Jefferies Analyst forecast on PRVA
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$30
Buy
41.51%
Upside
Reiterated
09/16/26
Jefferies Keeps Their Buy Rating on Privia Health Group (PRVA)
Barclays Analyst forecast on PRVA
Andrew Mok CFA
Barclays
Barclays
$24
Hold
13.21%
Upside
Reiterated
08/28/26
Barclays Reaffirms Their Hold Rating on Privia Health Group (PRVA)
Truist Financial Analyst forecast on PRVA
Jailendra Singh
Truist Financial
Truist Financial
$33
Buy
55.66%
Upside
Reiterated
08/13/26
Truist Financial Remains a Buy on Privia Health Group (PRVA)
Citi Analyst forecast on PRVA
Daniel Grosslight
Citi
Citi
$35
Buy
65.09%
Upside
Reiterated
08/10/26
Privia Health Group (PRVA) Gets a Buy from Citi
BTIG Analyst forecast on PRVA
David Larsen
BTIG
BTIG
$35
Buy
65.09%
Upside
Reiterated
08/09/26
Privia Health: Strong Q2 Results and Raised 2026 Outlook Underpin Buy Rating and Unchanged $35 Price Target
Canaccord Genuity Analyst forecast on PRVA
Richard Close
Canaccord Genuity
Canaccord Genuity
$34→$32
Buy
50.94%
Upside
Reiterated
08/07/26
Privia Health price target lowered to $32 from $34 at CanaccordPrivia Health price target lowered to $32 from $34 at Canaccord
Piper Sandler Analyst forecast on PRVA
Jessica Tassan
Piper Sandler
Piper Sandler
$36
Buy
69.81%
Upside
Reiterated
08/07/26
Piper Sandler Remains a Buy on Privia Health Group (PRVA)
BMO Capital Analyst forecast on PRVA
Sean Dodge
BMO Capital
BMO Capital
$30
Buy
41.51%
Upside
Reiterated
08/07/26
BMO Capital Keeps Their Buy Rating on Privia Health Group (PRVA)
William Blair Analyst forecast on PRVA
Ryan Daniels
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (NASDAQ: TNYA), Privia Health Group (NASDAQ: PRVA) and Praxis Precision Medicines (NASDAQ: PRAX)
Evercore ISI Analyst forecast on PRVA
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
$26→$32
Buy
50.94%
Upside
Reiterated
08/06/26
Evercore ISI Remains a Buy on Privia Health Group (PRVA)
TD Cowen Analyst forecast on PRVA
Ryan Langston
TD Cowen
TD Cowen
$30
Buy
41.51%
Upside
Reiterated
05/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham Analyst forecast on PRVA
Matthew Shea
Needham
Needham
$30
Buy
41.51%
Upside
Reiterated
05/07/26
Analysts' Top Healthcare Picks: Teleflex (TFX), Privia Health Group (PRVA)
J.P. Morgan Analyst forecast on PRVA
Lisa Gill
J.P. Morgan
J.P. Morgan
$35
Buy
65.09%
Upside
Reiterated
03/06/26
Analysts Are Bullish on These Healthcare Stocks: Sionna Therapeutics, Inc. (SION), Privia Health Group (PRVA)
KeyBanc Analyst forecast on PRVA
Matthew Gillmor CFA
KeyBanc
KeyBanc
―
Buy
―
Reiterated
02/27/26
Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (NASDAQ: XRAY), Solventum Corporation (NYSE: SOLV) and Privia Health Group (NASDAQ: PRVA)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on PRVA
Ryan Halsted
RBC Capital
RBC Capital
$31
Buy
46.23%
Upside
Reiterated
10/06/26
RBC Capital Reaffirms Their Buy Rating on Privia Health Group (PRVA)
Jefferies Analyst forecast on PRVA
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$30
Buy
41.51%
Upside
Reiterated
09/16/26
Jefferies Keeps Their Buy Rating on Privia Health Group (PRVA)
Barclays Analyst forecast on PRVA
Andrew Mok CFA
Barclays
Barclays
$24
Hold
13.21%
Upside
Reiterated
08/28/26
Barclays Reaffirms Their Hold Rating on Privia Health Group (PRVA)
Truist Financial Analyst forecast on PRVA
Jailendra Singh
Truist Financial
Truist Financial
$33
Buy
55.66%
Upside
Reiterated
08/13/26
Truist Financial Remains a Buy on Privia Health Group (PRVA)
Citi Analyst forecast on PRVA
Daniel Grosslight
Citi
Citi
$35
Buy
65.09%
Upside
Reiterated
08/10/26
Privia Health Group (PRVA) Gets a Buy from Citi
BTIG Analyst forecast on PRVA
David Larsen
BTIG
BTIG
$35
Buy
65.09%
Upside
Reiterated
08/09/26
Privia Health: Strong Q2 Results and Raised 2026 Outlook Underpin Buy Rating and Unchanged $35 Price Target
Canaccord Genuity Analyst forecast on PRVA
Richard Close
Canaccord Genuity
Canaccord Genuity
$34→$32
Buy
50.94%
Upside
Reiterated
08/07/26
Privia Health price target lowered to $32 from $34 at CanaccordPrivia Health price target lowered to $32 from $34 at Canaccord
Piper Sandler Analyst forecast on PRVA
Jessica Tassan
Piper Sandler
Piper Sandler
$36
Buy
69.81%
Upside
Reiterated
08/07/26
Piper Sandler Remains a Buy on Privia Health Group (PRVA)
BMO Capital Analyst forecast on PRVA
Sean Dodge
BMO Capital
BMO Capital
$30
Buy
41.51%
Upside
Reiterated
08/07/26
BMO Capital Keeps Their Buy Rating on Privia Health Group (PRVA)
William Blair Analyst forecast on PRVA
Ryan Daniels
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (NASDAQ: TNYA), Privia Health Group (NASDAQ: PRVA) and Praxis Precision Medicines (NASDAQ: PRAX)
Evercore ISI Analyst forecast on PRVA
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
$26→$32
Buy
50.94%
Upside
Reiterated
08/06/26
Evercore ISI Remains a Buy on Privia Health Group (PRVA)
TD Cowen Analyst forecast on PRVA
Ryan Langston
TD Cowen
TD Cowen
$30
Buy
41.51%
Upside
Reiterated
05/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham Analyst forecast on PRVA
Matthew Shea
Needham
Needham
$30
Buy
41.51%
Upside
Reiterated
05/07/26
Analysts' Top Healthcare Picks: Teleflex (TFX), Privia Health Group (PRVA)
J.P. Morgan Analyst forecast on PRVA
Lisa Gill
J.P. Morgan
J.P. Morgan
$35
Buy
65.09%
Upside
Reiterated
03/06/26
Analysts Are Bullish on These Healthcare Stocks: Sionna Therapeutics, Inc. (SION), Privia Health Group (PRVA)
KeyBanc Analyst forecast on PRVA
Matthew Gillmor CFA
KeyBanc
KeyBanc
―
Buy
―
Reiterated
02/27/26
Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (NASDAQ: XRAY), Solventum Corporation (NYSE: SOLV) and Privia Health Group (NASDAQ: PRVA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AMRXAmneal Pharmaceuticals
DNTHDianthus Therapeutics
ONCBeOne Medicines
IRLAIRulya Therapeutics
IDYAIDEAYA Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Privia Health Group

3 Months
Elizabeth Anderson CFAEvercore ISI
Success Rate
7/17 ratings generated profit
41%
Average Return
+0.72%
Copying Elizabeth Anderson CFA's trades and holding each position for 3 Months would result in 41.18% of your transactions generating a profit, with an average return of +0.72% per trade.
1 Year
Richard CloseCanaccord Genuity
Success Rate
8/21 ratings generated profit
38%
Average Return
-4.88%
Copying Richard Close's trades and holding each position for 1 Year would result in 38.10% of your transactions generating a profit, with an average return of -4.88% per trade.
2 Years
Sean DodgeBMO Capital
Success Rate
5/14 ratings generated profit
36%
Average Return
-4.74%
Copying Sean Dodge's trades and holding each position for 2 Years would result in 35.71% of your transactions generating a profit, with an average return of -4.74% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PRVA Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
4
3
6
5
6
Buy
13
13
8
9
7
Hold
1
1
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
17
15
15
14
In the current month, PRVA has received 13 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. PRVA average Analyst price target in the past 3 months is 31.80.
Each month's total comprises the sum of three months' worth of ratings.

PRVA Financial Forecast

PRVA Earnings Forecast

Next quarter’s earnings estimate for PRVA is $0.09 with a range of $0.06 to $0.13. The previous quarter’s EPS was $0.07. PRVA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year PRVA has Performed in-line its overall industry.
Next quarter’s earnings estimate for PRVA is $0.09 with a range of $0.06 to $0.13. The previous quarter’s EPS was $0.07. PRVA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year PRVA has Performed in-line its overall industry.

PRVA Sales Forecast

Next quarter’s sales forecast for PRVA is $610.74M with a range of $584.90M to $650.07M. The previous quarter’s sales results were $632.63M. PRVA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year PRVA has Performed in-line its overall industry.
Next quarter’s sales forecast for PRVA is $610.74M with a range of $584.90M to $650.07M. The previous quarter’s sales results were $632.63M. PRVA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year PRVA has Performed in-line its overall industry.

PRVA Stock Forecast FAQ

What is PRVA’s average 12-month price target, according to analysts?
Based on analyst ratings, Privia Health Group’s 12-month average price target is 31.80.
    What is PRVA’s upside potential, based on the analysts’ average price target?
    Privia Health Group has 50.00% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PRVA a Buy, Sell or Hold?
          Privia Health Group has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Privia Health Group’s price target?
            The average price target for Privia Health Group is 31.80. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $36.00 ,the lowest forecast is $24.00. The average price target represents 50.00% Increase from the current price of $21.2.
              What do analysts say about Privia Health Group?
              Privia Health Group’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of PRVA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.